Risk factor
Strong trading liquidity
Profitability factor
Very low or no dividends
About
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E.
Target Price
The average target price of LEGN is 60 and suggests 214% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell